Post-Traumatic Stress Disorder (PTSD) Market Research Report - Global Forecast till 2027

Post-Traumatic Stress Disorder (PTSD) Treatment Market Research Report: By Treatment (Psychotherapy (Cognitive Therapy, Exposure Therapy, Eye Movement Desensitization and Reprocessing (EMDR)), Medication, Antidepressants (Paroxetine, Sertraline, Mirtazapine, Amitriptyline or Phenelzine), Anti-Anxiety Medications (Beta-Blockers, Benzodiazepines), Prazosin)), By End User (Hospitals and Clinics, Ambulatory Surgical Centers) – Forecast to 2027

ID: MRFR/HC/6904-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data

The Global Post-Traumatic Stress Disorder (PTSD) Market is expected to cross USD 7.3 Billion by 2025 at a CAGR of 4.8%.


Market Synopsis

Post-Traumatic Stress Disorder (PTSD) occurs by experiencing life-threatening events such as natural disasters, serious accidents, military combat, terrorist incidents, or sexual assault in adult or childhood. Most survivors of trauma return to normal given a little time. However, some people will have stress reactions that do not go away on their own or may even get worse over time. These individuals might develop PTSD.  People who have PTSD often remember their experience through flashbacks or nightmares. They may have difficulty sleeping and may feel detached as these symptoms can be severe enough and might last long enough to impair the person’s daily life significantly.

Market Influencer

Increasing research regarding the use of cannabidiol (CBD) for the treatment of Post-Traumatic Stress Disorder (PTSD).

Market Drivers



  • Rising prevalence of PTSD

  • Increasing cases of cross-border tensions and violence- PTSD is most commonly associated with soldiers returning from war and has attracted widespread attention in the United States for its effects on veterans of the Iraq and Afghanistan wars. Thus, the increasing number of violence has increased the incidences of PTSD.

  • Rising sexual assault cases- The rate of homicides in Brazil is one of the highest in the World.

  • The rising number of emerging therapies for PTSD treatment

  • An increasing number of clinical trials

  • Increasing rehabilitation programs for injured military personnel

  • Rising incidences of road accidents

  • Launch of a new medication to manage the symptoms of post-traumatic stress disorder

  • A growing number of initiatives by public and private organizations


Market Restraints



  • Side effects due to some specific drugs


Post-Traumatic Stress Disorder (PTSD) Market Segmentation

By Treatment



  • Psychotherapy: In January 2017, nearly 46.6 million adults are affected by the mental disorder in the US. Behavioral therapies, such as cognitive-behavioral therapy (CBT), help to manage stress and deal with potential triggers as well as aid in enhancing self-esteem and altering negative thoughts. It is estimated that 32% to 53% of patients attend cognitive behavioral therapy every year.

  • Medication: It is projected to be the largest segment. Currently, paroxetine (Paxil) and sertraline (Zoloft) are the only medications that have been approved by the US Food and Drug Administration (FDA) for the treatment of PTSD.


By End-User



  • Hospitals and Clinics: The largest segment, hospitals, and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals who have PTSD. Growing awareness and increasing efficiency of hospital staff is projected to drive the growth of this segment during the forecast period.

  • Ambulatory Surgical Centers: A small segment, these centers provide immediate pain relief and rudimentary surgical care.

  • Others: This segment includes home care and senior citizen centers.


By Region



  • Americas: It is the largest region in the PTSD treatment market. Around 7.8% of Americans experiences PTSD at some point in their lives, with women (10.4%) twice as likely as men (5%) to develop PTSD. Approximately 5.2 million people of the US adults aged 18 to 54 have PTSD in 2017. 60.7% of men and 51.2% of women in the US have reported to experience at least one traumatic event. The traumatic events most often associated with PTSD are rape, childhood neglect, physical attack, combat exposure, sexual molestation, and childhood physical abuse.



  • Europe: Sexual violence is a severe public health and human rights problem with both short- and long-term consequences on women's health. In 2015, around 215,000 violent sexual crimes were recorded in the European region, of which 80,000 were rapes. Also, increasing (research & development) R&D in the therapeutics field and the presence of pharmaceutical giants along is providing a spur to the growth of the region.



  • Asia-Pacific: It is the fastest-growing region due to increasing rate of motor accidents. In India, 147,649 road accident cases were reported in 2015.



  • Middle East & Africa: The region is anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure.


Key Players



  • GlaxoSmithKline (UK)

  • Pfizer (US)

  • Eli Lilly and Company (US)

  • Lundbeck A/S (Denmark)

  • Azevan Pharmaceuticals (US)

  • Marinus Pharmaceuticals, Inc. (US)

  • Tonix Pharmaceuticals Holding Corp. (US)

  • Bionomics (Australia)

  • Greenstone LLC (US)

  • Mylan NV (US)



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2025: USD 7.3 Billion
  • 2027: Significant Value
  •   CAGR   4.8% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units    Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Treatment, End-User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Azevan Pharmaceuticals (US), Marinus Pharmaceuticals, Inc. (US), Bionomics (Australia), Greenstone LLC (US), GlaxoSmithKline (UK), Pfizer (US), Eli Lilly and Company (US), H. Lundbeck A/S (Denmark), Tonix Pharmaceuticals Holding Corp. (US), and Mylan NV (US)
      Key Market Opportunities

  • Increasing cases of cross-border tensions and violence- PTSD
  • Rising sexual assault cases
  •   Key Market Drivers

  • Rising prevalence of PTSD
  • The rising number of emerging therapies for PTSD treatment
  • An increasing number of clinical trials
  • Increasing rehabilitation programs for injured military personnel Rising incidences of road accidents
  • Launch of a new medication to manage the symptoms of post-traumatic stress disorder
  • A growing number of initiatives by public and private organizations


  • Frequently Asked Questions (FAQ) :


    The post-traumatic stress disorder market valuation would be USD 7.3 billion by 2025.

    The CAGR for post-traumatic stress disorder market would be 4.8% during the forecast period.

    The hospitals & clinics segment has the largest post-traumatic stress disorder market segment.

    The Americas would dominate post-traumatic stress disorder market.

    The Asia Pacific post-traumatic stress disorder market would be the fastest-growing regional market.

    Table of Contents

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    Chapter 5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    Chapter 6. Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment

    6.1 Introduction

    6.2 Psychotherapy

    6.2.1 Cognitive therapy

    6.2.2 Exposure therapy

    6.2.3 Eye movement desensitization and reprocessing (EMDR)

    6.3 Medication

    6.3.1 Antidepressants

    6.3.1.1 Paroxetine

    6.3.1.2 Sertraline

    6.3.1.3 Mirtazapine

    6.3.1.4 Amitriptyline or phenelzine

    6.3.2 Anti-anxiety medications

    6.3.2.1 Beta-blockers

    6.3.2.2 Benzodiazepines

    6.3.3 Prazosin

    Chapter 7. Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User

    7.1 Introduction

    7.2 Hospitals and Clinics

    7.3 Ambulatory Surgical Centers

    7.4 Others

    Chapter 8. Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Region

    8.1 Introduction

    8.2 Americas

    8.2.1 North America

    8.2.1.1 US

    8.2.1.2 Canada

    8.2.2 Latin America

    8.3 Europe

    8.3.1 Western Europe

    8.3.1.1 Germany

    8.3.1.2 France

    8.3.1.3 Italy

    8.3.1.4 Spain

    8.3.1.5 UK

    8.3.1.6 Rest of Western Europe

    8.3.2 Eastern Europe

    8.4 Asia-Pacific

    8.4.1 Japan

    8.4.2 China

    8.4.3 India

    8.4.4 Australia

    8.4.5 South Korea

    8.4.6 Rest of Asia-Pacific

    8.5 Middle East & Africa

    Chapter 9. Competitive Landscape

    9.1 Introduction

    9.2 Market Share Analysis

    9.3 Key Developments & Strategies

    9.3.1 Key Developments

    Chapter 10 Company Profiles

    10.1 GlaxoSmithKline

    10.1.1. Company Overview

    10.1.2. Financial Overview

    10.1.3. Products Offered

    10.1.4. Key Developments

    10.1.5. SWOT Analysis

    10.1.6. Key Strategies

    10.2 Pfizer

    10.2.1 Company Overview

    10.2.2 Financial Overview

    10.2.3 Products Offered

    10.2.4 Key Developments

    10.2.5 SWOT Analysis

    10.2.6 Key Strategies

    10.3 Eli Lilly and Company

    10.3.1 Company Overview

    10.3.2 Financial Overview

    10.3.3 Products Offered

    10.3.4 Key Developments

    10.3.5 SWOT Analysis

    10.3.6 Key Strategies

    10.4 H. Lundbeck A/S

    10.4.1 Company Overview

    10.4.2 Financial Overview

    10.4.3 Products Offered

    10.4.4 Key Developments

    10.4.5 SWOT Analysis

    10.4.5 Key Strategies

    10.5 Azevan Pharmaceuticals

    10.5.1 Company Overview

    10.5.2 Financial Overview

    10.5.3 Products Offered

    10.5.4 Key Developments

    10.5.5 SWOT Analysis

    10.5.6 Key Strategies

    10.6 Marinus Pharmaceuticals, Inc.

    10.6.1 Company Overview

    10.6.2 Financial Overview

    10.6.3 Products Offered

    10.6.4 Key Developments

    10.6.5 SWOT Analysis

    10.6.6 Key Strategies

    10.7 Tonix Pharmaceuticals Holding Corp.

    10.7.1 Company Overview

    10.7.2 Financial Overview

    10.7.3 Products Offered

    10.7.4 Key Developments

    10.7.5 SWOT Analysis

    10.7.6 Key Strategies

    10.8 Bionomics

    10.8.1 Company Overview

    10.8.2 Financial Overview

    10.8.3 Products Offered

    10.8.4 Key Developments

    10.8.5 SWOT Analysis

    10.8.6 Key Strategies

    10.9 Greenstone LLC

    10.9.1 Company Overview

    10.9.2 Financial Overview

    10.9.3 Products Offered

    10.9.4 Key Developments

    10.9.5 SWOT Analysis

    10.9.6 Key Strategies

    10.10 Mylan NV

    10.10.1 Company Overview

    10.10.2 Financial Overview

    10.10.3 Products Offered

    10.10.4 Key Developments

    10.10.5 SWOT Analysis

    10.10.6 Key Strategies

    10.11 Others

    Chapter 11. Appendix

    11.1. References

    11.2. Related Reports


    LIST OF TABLES

    Table 1 Global Post-Traumatic Stress Disorder (PTSD) Treatment Synopsis, 2020–2025

    Table 2 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market Estimates & Forecast, 2020-2027, (USD Million)

    Table 3 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Region, 2020-2027(USD Million)

    Table 4 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 5 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 6 Americas: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 7 Americas: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 8 Americas: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Region, 2020-2027(USD Million)

    Table 9 North America: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 10 North America: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 11 Latin America: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 12 Latin America: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 13 Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 14 Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 15 Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Region, 2020-2027(USD Million)

    Table 16 Western Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 17 Western Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 18 Eastern Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 19 Eastern Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 20 Asia-Pacific: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 21 Asia-Pacific: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)

    Table 22 Middle East & Africa: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by Treatment, 2020-2027(USD Million)

    Table 23 Middle East & Africa: Post-Traumatic Stress Disorder (PTSD) Treatment Market, by End User, 2020-2027(USD Million)


    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation of the Global Post-Traumatic Stress Disorder (PTSD) Treatment Market

    Figure 3 Market Dynamics for the Global Post-Traumatic Stress Disorder (PTSD) Treatment Market

    Figure 4 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Treatment, 2020

    Figure 5 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by End User, 2020

    Figure 6 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Region, 2020

    Figure 7 Americas: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Region, 2020

    Figure 8 North America: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2020

    Figure 9 Latin America: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2020

    Figure 10 Europe: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2020

    Figure 11 Asia-Pacific: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2020

    Figure 12 Middle East & Africa: Post-Traumatic Stress Disorder (PTSD) Treatment Market Share, by Country, 2020

    Figure 13 Global Post-Traumatic Stress Disorder (PTSD) Treatment Market: Company Share Analysis, 2020 (%)

    Figure 14 GlaxoSmithKline: Key Financials

    Figure 15 GlaxoSmithKline: Segmental Revenue

    Figure 16 GlaxoSmithKline: Regional Revenue

    Figure 17 Pfizer: Key Financials

    Figure 18 Pfizer: Segmental Revenue

    Figure 19 Pfizer: Regional Revenue

    Figure 20 Eli Lilly and Company: Key Financials

    Figure 21 Eli Lilly and Company: Segmental Revenue

    Figure 22 Eli Lilly and Company: Regional Revenue

    Figure 23 H. Lundbeck A/S: Key Financials

    Figure 24 H. Lundbeck A/S: Segmental Revenue

    Figure 25 H. Lundbeck A/S: Regional Revenue

    Figure 26 Azevan Pharmaceuticals: Key Financials

    Figure 27 Azevan Pharmaceuticals: Regional Revenue

    Figure 28 Azevan Pharmaceuticals: Key Financials

    Figure 29 Marinus Pharmaceuticals, Inc.: Segmental Revenue

    Figure 30 Marinus Pharmaceuticals, Inc.: Regional Revenue

    Figure 31 Marinus Pharmaceuticals, Inc.: Key Financials

    Figure 32 Tonix Pharmaceuticals Holding Corp.: Segmental Revenue

    Figure 33 Tonix Pharmaceuticals Holding Corp.: Regional Revenue

    Figure 34 Tonix Pharmaceuticals Holding Corp.: Key Financials

    Figure 35 Bionomics: Segmental Revenue

    Figure 36 Bionomics: Regional Revenue

    Figure 37 Bionomics: Key Financials

    Figure 38 Greenstone LLC: Segmental Revenue

    Figure 39 Greenstone LLC: Regional Revenue

    Figure 40 Greenstone LLC: Key Financials

    Figure 41 Mylan NV: Segmental Revenue

    Figure 42 Mylan NV: Regional Revenue

    Figure 43 Mylan NV: Key Financials




    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.